<DOC>
	<DOCNO>NCT00697099</DOCNO>
	<brief_summary>The primary objective compare efficacy daily [ q.d . ] subcutaneous [ s.c. ] injection Semuloparin sodium ( AVE5026 ) q.d . s.c. injection enoxaparin prevention Venous Thromboembolic Events [ VTE ] patient undergo elective total hip replacement surgery . The secondary objective evaluate safety AVE5026 patient undergo elective total hip replacement surgery , document AVE5026 exposure population .</brief_summary>
	<brief_title>Evaluation AVE5026 Compared Enoxaparin Prevention Thromboembolism Patients Undergoing Total Hip Replacement Surgery</brief_title>
	<detailed_description>Randomization take place prior first study drug injection ( randomization ratio 1:1 ) . The total duration observation per participant 35-42 day surgery broken follow : - 7 10-day double-blind treatment period ; - 28 35-day follow-up period . Mandatory bilateral venography lower limb perform 7 11 day surgery .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Elective total hip replacement surgery revision least one component prosthesis implant â‰¥ 6 month prior study entry . Any major orthopedic surgery 3 month prior study start ; Deep vein thrombosis pulmonary embolism within last 12 month know postphlebitic syndrome ; High risk bleeding ; Known allergy heparin enoxaparin ; Any contraindication performance venography ; End stage renal disease patient dialysis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>VTE prevention</keyword>
	<keyword>Total Hip Replacement</keyword>
	<keyword>Heparin Low-Molecular-Weight</keyword>
</DOC>